S&P 500 Analysis & ETF Trading

[kiy]

HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) was started with a Buy rating at Rodman & Renshaw on Monday, August 22, and it was assigned a $5 price target. This was up over 100% from the prior close of $2.44. The shares rose 2.5% to $2.50 right after the call on thin volume. Still, it closed Friday at $2.46, and trading volume is paltry in this tiny $18 million market cap.

HTG Molecular Diagnostics, Inc. develops and markets technology platforms that facilitate the routine use of complex molecular profiling. The company's HTG Edge and HTG EdgeSeq platforms consist of instrumentation, consumables, and software analytics that are used in molecular profiling applications, including tumor profiling, biomarker development and prospectively, and molecular diagnostic testing. The company's platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on various biological samples. It provides molecular profiling panels targeting late stage drug development programs with potential breakthrough therapies, such as immuno-oncology.
Daily

60minute



HTGM